These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

921 related items for PubMed ID: 31665020

  • 1. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
    Li C, Li C, Zhi C, Liang W, Wang X, Chen X, Lv T, Shen Q, Song Y, Lin D, Liu H.
    J Transl Med; 2019 Oct 29; 17(1):355. PubMed ID: 31665020
    [Abstract] [Full Text] [Related]

  • 2. Blood exosome PD-L1 is associated with PD-L1 expression measured by immunohistochemistry, and lymph node metastasis in lung cancer.
    Zhang Z, Jin W, Xu K, Zheng X, Zhou Y, Luo M, Yan C, Zheng X, Jin E.
    Tissue Cell; 2022 Dec 29; 79():101941. PubMed ID: 36228365
    [Abstract] [Full Text] [Related]

  • 3. Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer.
    Gao J, Qiu X, Li X, Fan H, Zhang F, Lv T, Song Y.
    Biochem Biophys Res Commun; 2018 Apr 06; 498(3):409-415. PubMed ID: 29452091
    [Abstract] [Full Text] [Related]

  • 4. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer.
    Shimada Y, Matsubayashi J, Kudo Y, Maehara S, Takeuchi S, Hagiwara M, Kakihana M, Ohira T, Nagao T, Ikeda N.
    Sci Rep; 2021 Apr 09; 11(1):7830. PubMed ID: 33837261
    [Abstract] [Full Text] [Related]

  • 5. Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients.
    Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL.
    Clin Cancer Res; 2018 Feb 15; 24(4):896-905. PubMed ID: 29233903
    [Abstract] [Full Text] [Related]

  • 6. Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients.
    He J, Pan Y, Guo Y, Li B, Tang Y.
    J Immunother; 2020 Jun 15; 43(5):156-164. PubMed ID: 32168233
    [Abstract] [Full Text] [Related]

  • 7. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
    Okuma Y, Wakui H, Utsumi H, Sagawa Y, Hosomi Y, Kuwano K, Homma S.
    Clin Lung Cancer; 2018 Sep 15; 19(5):410-417.e1. PubMed ID: 29859759
    [Abstract] [Full Text] [Related]

  • 8. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
    Yamada T, Miki Y, Suzuki M, Kondoh O, Saito-Koyama R, Ono K, Okada Y, Sasano H.
    Cancer Med; 2022 Jan 15; 11(2):479-491. PubMed ID: 34907653
    [Abstract] [Full Text] [Related]

  • 9. The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
    Ren S, Tian Q, Amar N, Yu H, Rivard CJ, Caldwell C, Ng TL, Tu M, Liu Y, Gao D, Ellison K, Suda K, Rozeboom L, Rivalland G, Mitchell P, Zhou C, Hirsch FR.
    Lung Cancer; 2018 Nov 15; 125():115-120. PubMed ID: 30429008
    [Abstract] [Full Text] [Related]

  • 10. Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.
    Yang Q, Chen M, Gu J, Niu K, Zhao X, Zheng L, Xu Z, Yu Y, Li F, Meng L, Chen Z, Zhuo W, Zhang L, Sun J.
    Front Immunol; 2021 Nov 15; 12():665133. PubMed ID: 33936103
    [Abstract] [Full Text] [Related]

  • 11. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.
    Takeuchi M, Doi T, Obayashi K, Hirai A, Yoneda K, Tanaka F, Iwai Y.
    Immunol Lett; 2018 Apr 15; 196():155-160. PubMed ID: 29366663
    [Abstract] [Full Text] [Related]

  • 12. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, Jin X, Steele KE, Robbins PB, Blake-Haskins JA, Walker J.
    Diagn Pathol; 2016 Oct 08; 11(1):95. PubMed ID: 27717372
    [Abstract] [Full Text] [Related]

  • 13. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer.
    Peng XX, Yu R, Wu X, Wu SY, Pi C, Chen ZH, Zhang XC, Gao CY, Shao YW, Liu L, Wu YL, Zhou Q.
    J Immunother Cancer; 2020 Jan 08; 8(1):. PubMed ID: 31959728
    [Abstract] [Full Text] [Related]

  • 14. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B, Wang WL, Gong Y, Zhao J, Kalhor N, Prieto V, Staerkel G, Roy-Chowdhuri S.
    Cancer Cytopathol; 2018 May 08; 126(5):342-352. PubMed ID: 29499101
    [Abstract] [Full Text] [Related]

  • 15. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.
    Akamine T, Takada K, Toyokawa G, Kinoshita F, Matsubara T, Kozuma Y, Haratake N, Takamori S, Hirai F, Tagawa T, Okamoto T, Yoneshima Y, Okamoto I, Shimokawa M, Oda Y, Nakanishi Y, Maehara Y.
    Surg Oncol; 2018 Mar 08; 27(1):88-94. PubMed ID: 29549910
    [Abstract] [Full Text] [Related]

  • 16. Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib.
    Sorensen SF, Demuth C, Weber B, Sorensen BS, Meldgaard P.
    Lung Cancer; 2016 Oct 08; 100():77-84. PubMed ID: 27597284
    [Abstract] [Full Text] [Related]

  • 17. Clinicopathological characteristics and tumor infiltrating immune cells associations of PD-L1 tumor expression in non-small cell lung cancer patients.
    Aazzane O, Bakhtaoui FZ, Stitou S, Fellah H, Karkouri M.
    Tunis Med; 2024 Apr 05; 102(4):223-228. PubMed ID: 38746962
    [Abstract] [Full Text] [Related]

  • 18. Tumor-derived exosomal lncRNA GAS5 as a biomarker for early-stage non-small-cell lung cancer diagnosis.
    Li C, Lv Y, Shao C, Chen C, Zhang T, Wei Y, Fan H, Lv T, Liu H, Song Y.
    J Cell Physiol; 2019 Nov 05; 234(11):20721-20727. PubMed ID: 31032916
    [Abstract] [Full Text] [Related]

  • 19. Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.
    Karatrasoglou EA, Chatziandreou I, Sakellariou S, Stamopoulos K, Kavantzas N, Lazaris AC, Korkolopoulou P, Saetta AA.
    Virchows Arch; 2020 Aug 05; 477(2):207-217. PubMed ID: 31989260
    [Abstract] [Full Text] [Related]

  • 20. Prognostic significance of programmed cell death ligand 1 blood markers in non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Zhang N, Chang J, Liu P, Tian X, Yu J.
    Front Immunol; 2024 Aug 05; 15():1400262. PubMed ID: 38915398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.